EVOKE MEDICAL RECEIVES NIH PHASE II GRANT
July 21, 2018, We are pleased to announce that Evoke Medical has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
This highly competitive grant will provide Evoke Medical with the necessary funding and resources to further advance its groundbreaking research in the field of medical devices for the treatment of degenerative disc disease. With this grant, Evoke Medical will be able to move forward with the development of innovative and minimally invasive devices, such as the smart human powered electrically stimulating fusion cage, bringing us one step closer to improving the lives of millions of patients suffering from degenerative disc disease.
The Phase II SBIR grant is a significant milestone for Evoke Medical, as it represents a validation of the company's research and the potential impact it can have on the healthcare industry. We are thrilled to have the support of NIH and are grateful for the opportunity to continue our research with their support.
We would like to express our gratitude to the NIH for their ongoing commitment to supporting innovative small businesses like Evoke Medical, as well as our team of dedicated researchers and scientists who have worked tirelessly to achieve this success.
We look forward to continuing our collaboration with NIH and the broader scientific community as we work towards our ultimate goal of developing safe and effective medical devices for the treatment of degenerative disc disease, a condition that affects millions of people worldwide.
PHASE II OUTCOMES
The animal study aimed to assess the safety and efficacy of smart patient powered electrically stimulating fusion cage for the treatment of degenerative disc disease. The randomized comparative study involved ten sheep followed to 4 months.
We are excited to report that the results of the animal study have exceeded our expectations. The sheep study demonstrated the miniaturized TLIF form factor did have an effect and the product design was adequate to demonstrate safety with no exuberant bone growth noted. We also gained keen insight into the manufacturability of the product through this grant and pre-clinical work that was completed. These findings suggest that patient-powered electrical stimulation in an interbody cage has the potential to significantly improve the quality of life of patients suffering from degenerative disc disease and failed fusions.
The success of the animal study is a significant milestone for Evoke Medical and a testament to the company's dedication to advancing medical research. We would like to express our gratitude to the NIH for their ongoing support and investment in innovative small businesses like ours.
Moving forward, Evoke Medical will continue to build on these promising results and work towards bringing this patient powered electrical stimulating interbody cage to the market. We remain committed to working closely with the NIH and the broader scientific community to develop safe and effective treatments for degenerative disc disease and improve the lives of patients around the world.
We look forward to sharing more updates on our progress in the near future.